In order to optimally develop and use those therapies, it has become critical to understand how exposure to CDK4/6i changes the genomic landscape of metastatic tumors, in particular regarding mutations associated with treatment outcomes such as TP53 and ESR1. Our results based on RWD, and validated using clinical trial data, offer five conclusions to that question. This evidence concerns the gene CDK4 and metastatic neoplasm.